Get started
Work

mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses?

Year: 2014
Type: article
Abstract: Rapamycin is a macrolide antibiotic originally isolated from Streptomyces hygroscopicus, a bacterium isolated from a soil sample collected on Easter Island. It was found to suppress the immune system by blocking T-cell activation and proliferation, and was approved by the FDA for prophylaxis against organ rejection in renal transplant patients in 1999. Molecular studies first defined a role for rapamycin in complex with a small isomerase FKBP12 in inhibiting the activity of kinases TOR1 (TOR=Target of Rapamycin) and TOR2 in yeast.
Source: EBioMedicine
DOI: 10.1016/j.ebiom.2014.12.011
Language: English
Open Access status: gold
Estimated APC paid: $5,780
Funders: Tuberous Sclerosis Alliance, LAM Foundation, Broad Institute, European Commission, National Institutes of Health, Fourth Framework Programme, National Cancer Institute
Awards: G1671744939, G5458257381, Long-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy – tuberous sclerosis complex, G9000332944, Molecular Pathogenesis of the Hamartoma Syndromes, Physician Scientist Training in Cancer Research
OpenAlex ID: W2097426323
FWCI: 0.273
Cites: 10
Cited by: 19
Related to: 10